Molecular Pathology Approach to Cancer
Molecular Pathology Approach to Cancer will provide a discussion of current concepts in molecular pathology, molecular pathology methods practicing pathologists and oncologists, residents and fellows in pathology and oncology, and molecular biologists with an interest in molecular pathology and precision medicine.
Confirmed Speakers

Topics include
Reduced registra for EACR/OECI Find out more at ww Fabrice André (France) Judith Bovee (Netherlands) David Huntsman (Canada) Andreas Jung (Germany) Marc Ladanyi (USA) Alberto Mantovani (Italy) What can we learn from single patients?
The Peeper laboratory develops and uses function-based genomic approaches to better understand the mechanistic principles of cancer progression, and to identify novel therapeutic targets for achieving more durable clinical responses for cancer patients. We have two main strategies: first, we wish to increase our understanding of how cancer cells originate and function and define their rewired signalling networks. This will expose their weaknesses and allow for the identification of specific and pharmacologically tractable vulnerabilities. Second, we wish to determine how we can manipulate various cell types from the patient's own immune system to enhance its cytotoxicity towards tumour cells. This approach should uncover new therapeutic targets on immune cells. By focusing on these two main research arms, our objective is to contribute to the development of combinatorial therapies, which simultaneously eliminate the patients' tumour cells and harness their immune cells.
Recent publications:
• Iskit S, Lieftink C, Halonen P, Shahrabi A, Possik PA, Beijersbergen RL, Peeper DS.
Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer. 
Massively-parallel sequencing
Serena Nik-Zainal (UK)
The recent increase in the speed of sequencing offered by modern sequencing technologies permits an unprecedented degree of exploration of the human genome. No longer are we restricted to PCRdefined fragments of protein-coding exons, we can now investigate all the genetic material in human cells. I explain the principles underlying massively-parallel sequencing giving some insight into the advances as well as the difficulties posed by processing of the enormous datasets generated by modern sequencing experiments.
Cancer is the ultimate disorder of the genome, characterised by not just one or two mutations, but hundreds to thousands of acquired mutations that have been accrued through the development of a tumour. Utilising the extraordinary surge in scale as well as the digital nature of massively-parallel sequencing, I explain some of the recent highlights into tumour biology offered by these modern methods: cancer gene discovery, mutation signatures and cancer evolution.
Reading:
Cancer List of relevant publications: The evolution of pathology
Dept. of Medical Sciences, University of Trieste
Today research conducted in patients' tissues is one of the most important fields of development in oncology. This is especially important for oncology because there are many more actionable mutations in each patient's cancer than those we are considering for prognosis, diagnosis and treatment. The introduction of new drugs in clinics by regulatory organizations is very slow, and classical trial procedures need very long time to be completed. This is related to the high level of complexity of cancer progression mostly caused by clonal evolution, due to intratumour heterogeneity. Because of this, large tumour molecular categories seem to be insufficient to respond to the very high level of clinical variability. Clinical research presents anyway a high risk of irreproducibility of molecular analysis. The major problems are related to preanalytical conditions of biological samples, standardized analytical methods, and cellular and molecular heterogeneity. To shorten the time to develop a diffused and reproducible clinical research, new types of approaches are designed today, such as N-1 trials. In this case, the single patient can be a specific trial with information collected in different time periods. New clinical research approaches are already being planned by European organizations such as the OECI (Organisation of European Cancer Institutes), which next June will discuss the possibility to effectively perform reproducible clinical research in patients' biological material, and to activate large networks of N-1 trials in the future.
The problems of reproducibility are also tackled with European organizations such as the new SPIDIA4P project for standardization of preanalytical conditions of biological material, and the OECI for the development of standardized analytical procedures, such as liquid biopsies and clinical NGS. In the European Society of Pathology, the tentative drafting of new protocols is being undertaken to overcome heterogeneity with better sampling. The European Infrustructure of Biobanking (BBMRI-ERIC) has recently developed a new expert centre for molecular analyses in clinical tissues (ATMA-EC) to reach higher levels of standardization of molecular analysis.
Clinical research is for today's patients, as an integral part of the clinical activity. This type of research is absolutely necessary for the development of clinical oncology, and presents some new important bioethical considerations.
Speaker profiles
The molecular pathology of breast cancer The genetic alterations identified in breast cancer are amplification of between 10 and 20 oncogenes (or genomic regions with as yet not an identified "driving" oncogenes) and mutations in oncogenes and tumour suppressor genes. Over 1,000 breast carcinomas have been subjected to whole genome sequence analysis or whole exome sequence analysis. From this work it has become clear that there are only three mutations that occur in >10% of breast carcinomas (those in P53, GATA3 and PIK3CA) and also few genes that are amplified in >10% of cases (including HER2, cyclinD1 and CMYC). There are hundreds of mutations that each occur at low frequency in breast cancer.
Gene expression profiling has led to the identification of subsets of breast cancer revealed by unsupervised classification termed basal type, ERBB2 like, luminal A, luminal B and normal epithelial like cancers; and supervised classification has revealed good-and poor prognosis subtypes. A growing number of prognostic tests based on gene expression profiling is used clinically. While identification of prognostic gene expression profiles has been successful, it has not been possible yet to identify robust clinically useful predictors of response to systemic treatment.
Integration of histologic, genomic and gene expression data of breast carcinomas is leading to an increasingly refined classification that elucidates the initiation and progression of breast cancer at the molecular level; and the identification of novel prognostic and predictive markers that can guide treatment of individual patients. Speaker profiles
The molecular pathology of ovarian cancer
David Huntsman (Canada)
The three most common types of ovarian cancer, high grade serous, clear cell and endometrioid all arise from cells that are not native to ovary. The clinical and biologic distinctions between these cancers are shaped by both cell of origin (cell context) and genomic features. This talk will focus on how our emerging understanding of histogenesis and genomics is leading to improved diagnostics as well as prevention and management strategies. Along with a review of recent publications our unpublished data on i) potential distinct cells of origin for clear cell and endometrioid carcinomas, ii) mutation and the transformation of endometriosis to ovarian cancer, iii) the fallopian tube and ovarian cancer prevention and iv) the genomic landscape of high grade serous carcinomas will be presented.
Among rare ovarian cancers granulosa cell tumours, sertoli leydig tumours and small cell hypercalcemic ovarian cancers are clinically and biologically distinct. In the past few years the key mutations underpinning these mutations have been discovered. This has led to improved diagnostics for granulosa cell tumours and small cell hypercalcemic ovarian cancer. The discovery of pathognomonic mutations has led to the development of model systems and a better understanding of all three cancer types and for small cell ovarian cancers new treatment strategies.
Recent publications:
Hughes, C. S. et al. 
The molecular pathology of endometrial cancer
Britta Weigelt (USA)
The uterine corpus represents the most common site for gynecologic malignancies in the western world. Endometrial cancer comprises a heterogeneous group of tumors with distinct risk factors, histopathological features, and clinical outcome. Genomic studies are continuing to unveil the constellation of genetic alterations in uterine cancer, which have the potential to be used as molecular markers for classification, risk-stratification and therapy decision-making.
This presentation will focus on the molecular classification of endometrial carcinomas, including the different types of hypermutated cancers, the advances in the genetic characterization of synchronous endometrial and ovarian cancers as well as of rare subtypes of the disease, including uterine carcinosarcomas. The limitations of the current classification systems and the challenges for the development of a taxonomy for endometrial cancer that accurately reflects its molecular characteristics and clinical behavior will be discussed.
Recent publications:
• 
The molecular pathology of bone tumours
Judith Bovée (Netherlands)
Professor Judith V.M.G. Bovée is a clinician scientist at the Department of Pathology, LUMC, with a special focus on bone and soft tissue tumours. Her aim is to crosslink patient care (diagnostic pathology of bone and soft tissue tumours) with basic research (elucidating the molecular events underlying sarcoma development and progression) in order to establish improved diagnosis, prognosis and treatment for patients with bone and soft tissue tumours.
Bone tumours are considered difficult by most pathologists, as they are rare, have overlapping morphology, need radiological correlation, and the usefullness of immunohistochemistry is limited. Therefore, conventional morphology is still the cornerstone of the diagnosis. Over the past decade, more knowledge has become available on the molecular background of bone tumours. In sarcomas, we recognize three molecular classes of bone tumours. First, tumors with deregulated transcription, which is usually due to a translocation in which the fusion product acts as an aberrant transcription factor, include for instance Ewing sarcoma. Second, deregulated signalling can be caused by specific amplification (e.g. MDM2 in low grade osteosarcoma), specific gene mutation (e.g. GNAS mutation in fibrous dysplasia) or a translocation causing a promotor swab leading to upregulation of a specific gene (e.g. USP6 rearrangement in aneurysmal bone cyst or GRM1 rearrangement in chondromyxoid fibroma). Third, the largest subgroup includes sarcomas with genetic instability and complex karyotypes. These include osteosarcoma and high grade chondrosarcoma. Technical advancements including next generation sequencing have revealed many new genetic alterations in rare bone tumours over the past few years, which helps us to understand their histogenesis, may assist in the differential diagnosis and may provide targets for novel therapeutic strategies.
Recent publications:
• Szuhai K, Cleton-Jansen AM, Hogendoorn PCW, Bovée JVMG, Molecular pathology and its diagnostic use in bone tumors., Cancer Genet. The molecular pathology of soft tissue sarcomas
Matt van de Rijn (USA)
In this talk I will present a molecular approach to the diagnosis of sarcoma. Sarcomas are malignant tumors that originate from connective tissue cells such as muscle cells, fibroblasts and adipocytes. The disease is rare with approximately 11,000 new cases per year in the United States for soft tissue tumors and approximately 3,000 new cases per year for bone sarcomas. Within this group of tumors there are over 50 distinct diagnostic entities. As a result most clinicians only rarely see cases for each subtype leading to unfamiliarity with treatment options but also with diagnostic classifications. Accurate diagnosis is of course a prerequisite for appropriate therapy and this is especially the case when one considers that novel targeted therapies are continuously being developed. The classification of sarcomas has been based on the morphologic recognition of the different appearances of these tumors and has been supported by immunohistochemistry studies in the past decades.
More recently it has been recognized that on a molecular level, two broad categories of sarcoma can be identified. One group of sarcomas is characterized by highly complex genetic abnormalities in which to date no specific patterns can be identified. Members of this category include leiomyosarcomas, undifferentiated pleomorphic sarcomas and malignant peripheral nerve sheath tumors. The second group of sarcomas has simple genetic changes that consist of chromosomal translocations, gene amplifications, and oncogenic mutations. Many of these simple genetic changes are actually relevant to the diagnosis of these tumor types as they occur specifically in only one tumor type. In addition they form the basis for much of the targeted therapy approaches that are in practice or are being developed.
Specific chromosomal translocations have been identified for more than 40 soft tissue sarcomas and benign soft tissue tumors and this number can be expected to increase. It is not cost effective to maintain a set of individual diagnostic tests (either by RT-PCR or by FISH) for these rare disease in a CLIA-approved manner in diagnostic molecular laboratories. A number of NGS-based approaches have recently been developed that allow for the use of a single test to detect multiple translocations. References: Speaker profiles
The molecular pathology of lung cancer
Marc Ladanyi (USA)
Tumor genetic testing is now standard of care for patients with non-small cell lung cancer. Lung adenocarcinomas, which account for approximately 50% of lung cancers, are molecularly sub-classified and their therapy dictated by the presence of distinct molecular alterations including EGFR mutations and ALK or ROS1 fusions that confer sensitivity to selective kinase inhibitors. Additional alterations such as BRAF V600E, RET fusions, and ERBB2 amplifications are found in smaller subsets of patients, but when present may also predict for response to targeted inhibitors. In other patients, defined oncogenic drivers such as KRAS mutations are detected for which preclinical studies have nominated targeted approaches, but the clinical utility of such therapies has yet to be established. As a result of advances in DNA sequencing, the prospective molecular analysis of tumors for mutations in hundreds of cancer-associated genes is now feasible using multiplexed assays that use as input small quantities of formalin fixed paraffin embedded tissue.
Through an institution-wide initiative in clinical cancer genomics initiated in 2014, we have implemented large scale genomic profiling for targetable cancer drivers and other cancer-relevant alterations in all patients with advanced solid cancers. Over 15,000 patients have been profiled using the MSK-IMPACT capture-based, targeted DNAseq assay. Subsets of patients have also been studied for oncogenic fusions by targeted RNAseq or for germline cancer predisposition alleles. An overview of our experience will be presented.
Recent publications:
The molecular pathology of melanomas
Amaya Viros (UK)
Ultraviolet radiation (UVR) is the only environmental carcinogen driving cutaneous melanoma. UVR contributes to malignant progression through direct DNA damage and by inducing an inflammatory response. There is a great variability in the number of mutations detected by massively parallel DNA sequencing in different melanoma samples. The specific contribution of UVR to distinct melanoma subtypes is unknown. Mouse models of melanoma driven by the more relevant melanoma oncogenes can help dissect the exact contribution of the environment to distinct molecularly defined melanoma subtypes. In the last 16 years we have witnessed a change in the accepted paradigm of the essence of cancer, crystallized once more by Hanahan and Weinberg in a review in Cell in 2011. The new version of the paradigm includes the microenvironment, the ecological niche, as a key component of cancer. In brief, development of a clinically observed tumor is associated with the recruitment of "corrupted policemen", macrophages, and other white blood cells, which help cancer to progress. Concomitantly, the directors of the adaptive immunity orchestra, the T cells, are put to sleep; they are like a "Ferrari" with many brakes on. The brakes we call "checkpoints", and the "corrupted policemen" help holding the brakes on.
Viros
The change in paradigm together with progress in identifying the cells and molecules involved in immunity have led to a revolution in the fight against cancer. We use antibodies, cytokines and anticytokine molecules to treat patients and to protect them from toxicity; we release brakes called checkpoints; we are learning how to stop corrupted policemen and how to reeducate and increase in number and arm the army of our soldiers.
The World Health Organization (WHO) Classification of Tumours of the Central Nervous System (CNS) provides an international standard for the diagnosis of these neoplasms and serves as an important guide for use in the design of studies monitoring response to therapy and clinical outcome. In May 2016, an update of the 4th edition of the WHO CNS Tumour Classification was officially released 1 . This revised WHO Classification represents a paradigm shift as, for the first time, the definition of multiple CNS tumour entities is now partly based on particular genotypic characteristics. The most substantial changes in the WHO 2016 Classification concern gliomas and embryonal tumors 2 . According to the 2016 classification, most diffuse gliomas are diagnosed based on presence/absence of IDH mutation and 1p/19q codeletion. Medulloblastomas, the most frequent 'embryonal' CNS tumours in children, are now ideally classified based on molecular characteristics as well (WNT-activated; SHH-activated & TP53-wildtype; SHH-activated & TP53-mutant; non-WNT/non-SHH). Additional examples of (pediatric) CNS tumours that are molecularly defined are atypical teratoid/rhabdoid tumour (AT/RT; typically carrying a SMARCB1 or, much less frequently, a SMARCA4 mutation), a particular subtype of ependymoma (RELA fusion-positive), and diffuse midline glioma (H3 K27M-mutant). Incorporation of these molecular markers in the definition of CNS tumours not only allows for a much more precise and reproducible diagnosis of gliomas and embryonal neoplasms, but also carries important prognostic and/or predictive meaning. The lecture will cover 'what's new' in the WHO 2016 Classification with a focus on the most relevant molecular markers for the diagnosis of CNS tumours and on tools that can be used to assess these markers in daily clinical practice.
Molecular testing in clinical practice
Marc Ladanyi (USA) Tumor genetic testing is now standard of care for patients with non-small cell lung cancer. Lung adenocarcinomas, which account for approximately 50% of lung cancers, are molecularly sub-classified and their therapy dictated by the presence of distinct molecular alterations including EGFR mutations and ALK or ROS1 fusions that confer sensitivity to selective kinase inhibitors. Additional alterations such as BRAF V600E, RET fusions, and ERBB2 amplifications are found in smaller subsets of patients, but when present may also predict for response to targeted inhibitors. In other patients, defined oncogenic drivers such as KRAS mutations are detected for which preclinical studies have nominated targeted approaches, but the clinical utility of such therapies has yet to be established. As a result of advances in DNA sequencing, the prospective molecular analysis of tumors for mutations in hundreds of cancer-associated genes is now feasible using multiplexed assays that use as input small quantities of formalin fixed paraffin embedded tissue.
Through an institution-wide initiative in clinical cancer genomics initiated in 2014, we have implemented large scale genomic profiling for targetable cancer drivers and other cancer-relevant alterations in all patients with advanced solid cancers. Over 15,000 patients have been profiled using the MSK-IMPACT capture-based, targeted DNAseq assay. Subsets of patients have also been studied for oncogenic fusions by targeted RNAseq or for germline cancer predisposition alleles. An overview of our experience will be presented. 
